Pertussis Outbreak Among Adults at an Oil RefineryIllinois, August-October 2002
On September 16, 2002, the Crawford County Health Department (CCHD) reported to the Illinois Department of Public Health (IDPH) four cases of cough illness among workers at an oil refinery (total worker population: 750) in Crawford County, Illinois. On August 14, a worker aged 39 years reported to the plant's health unit with a cough lasting 14 days. On the same day, the worker's supervisor aged 50 years visited the health unit for a paroxysmal cough of 3 days' duration and an incident of cough syncope. Both patients were referred to private health-care providers; blood samples from both patients had serologic test results suggestive of recent Bordetella pertussis infection, and CCHD was contacted. On September 18, IDPH and CCHD initiated active surveillance and case investigations. This report summarizes the results of that investigation, which found that during August 1-October 9, pertussis was diagnosed in 15 (10%) of 150 oil refinery workers from two separate operations (n=95) and maintenance (n=55) complexes, who were linked by contact with the ill supervisor. Through enhanced case finding, 24 cases of pertussis, 21 (88%) of which occurred in adults aged >20 years, were identified in this outbreak, underscoring the need to recognize this highly infectious disease in adults and to improve national diagnostic and preventive strategies.
A clinical case was defined as an acute cough illness lasting >2 weeks in a person with 1) at least one of the following: paroxysms of coughing, inspiratory "whoop," or post-tussive vomiting, without other apparent cause or 2) >14 days of cough in a person in an outbreak setting. A confirmed case was defined as a cough illness of any duration in a person with isolation by culture of B. pertussis or a case that met the clinical case definition and was confirmed by polymerase chain reaction (PCR) for B. pertussis DNA or by epidemiologic linkage to a laboratory-confirmed case. A probable case met the clinical case definition, was not laboratory-confirmed, and was not linked by direct contact with a laboratoryconfirmed case. At the oil refinery, any worker reporting a cough illness to the health unit was referred to the local community hospital for evaluation for pertussis and interviewed by CCHD or IDPH staff to establish onset of illness, symptoms, area of work and work schedules, and information on all close contacts. Community cases were identified through standard IDPH case report forms submitted by health-care providers to CCHD for suspected cases of pertussis and then reviewed by the IDPH immunization section to determine if the case definition was met.
As of December 13, a total of 17 cases of pertussis have been associated with the oil refinery: four confirmed cases (including one culture-positive case, one PCR-positive case, and two epidemiologically linked cases) and 13 probable cases; 10 patients were males. A pulsed-field gel electrophoresis (PFGE) DNA fingerprint from the B. pertussis isolate from the culture-confirmed case (illness onset date: September 10) was PFGE profile 13. The median age of patients was 40 years (range: 16-53 years). Six patients worked in the same work unit. Eight of 14 patients tested by a private diagnostic laboratory had serologic testing results (anti-B. pertussis IgA, IgM, or IgG enzyme immunoassay) suggestive of recent B. pertussis infection. In addition to the 17 patients identified from the oil refinery, seven patients in the community who were unrelated epidemiologically to the oil refinery also were identified as having probable cases of pertussis; four were males with a median age of 24 years (range: 5-33 years). All 24 patients ( Figure) received treatment with macrolide antibiotics and were encouraged to be tested for pertussis by PCR and nasopharyngeal culture. On September 19, with the cooperation of the oil refinery management, 150 close work contacts of the 17 patients at the oil refinery plant were prescribed azithromycin prophylaxis at a dose schedule of 500 mg for the first day, followed by 250 mg daily for the next 4 days.
Other than a meeting lasting approximately 5 minutes conducted indoors each morning, daily work assignments at the plant are performed outdoors. However, workers may congregate in an indoor dining area reserved for lunch.
No cases of pertussis at the oil refinery have been reported since October 9. School officials and health-care providers within the community have been given guidelines on pertussis case recognition, reporting, and prophylaxis measures. IDPH and the local health department continue to perform ongoing case ascertainment. community because immunity from childhood vaccination declines beginning 5-15 years after the last pertussis vaccine dose (3) . Despite increasing recognition of pertussis as a disease affecting older children and adults, pertussis often is overlooked in the differential diagnosis of cough illness in this population (4) . Pertussis can be highly infectious during the 3 weeks after illness onset, and infection can spread to exposed infants, who have the highest rates for complications and death (5) (Box). In this outbreak, pertussis was not considered initially in the index patient's 14-day cough illness until the patient's supervisor reported to the oil refinery health unit concurrently with cough syncope, triggering referral of both patients to the local community hospital for evaluation for pertussis. Emblematic in this outbreak was the protracted duration of cough symptoms in the first patient, followed by a comprehensive public health response once several close contacts became infected and, late in the outbreak, B. pertussis was cultured successfully from an oil refinery worker; isolation of B. pertussis from an adult is uncommon.
In Illinois, 46 of 191 cases (24%) of reported pertussis in 2001 occurred in adults aged >20 years (incidence rate: 0.5 per 100,000 population), a proportion similar to that of cases in the United States among this age group (1). Persons aged 10-19 years comprised 18% of all cases in 2001 in Illinois. Waning vaccine-induced immunity probably accounts for susceptibility to B. pertussis infection in both adults and adolescents (3, 6) . Since the 1980s, the reported incidence rates in adolescents and adults in the United States have increased as a result of changes in reporting, a true increase in incidence, or both (1, 2) . In 1995, the case definition for pertussis was expanded to include PCR-positive tests and epidemiologic linking of pertussis cases as confirmation criteria. In addition, a possible increase in awareness of pertussis in older age groups within the medical community during the 1990s might have contributed to increased diagnosis rates in this population (7) .
Adults with pertussis can have mild symptoms and might not seek medical care, and clinicians might not consider pertussis as a cause of illness (8). Although the fastidious B. pertussis bacterium often cannot be isolated, to confirm diagnosis in symptomatic adults, health-care providers should obtain a nasopharyngeal aspirate or swab for B. pertussis culture within 2 weeks of cough onset. In this outbreak, serologic testing for diagnosis of recent B. pertussis infection was performed in the majority of cases. No serologic assay for a single convalescent sera is currently approved or recommended for serodiagnosis of pertussis. Because adults might report to health-care providers late in the disease course, a standardized and valid serologic test is needed to diagnose recent B. pertussis infection in adults (9).
As one of several state health departments with enhanced pertussis surveillance systems, IDPH analyzes B. pertussis iso-BOX. Epidemiology, diagnosis, treatment, and prevention of pertussis (whooping cough)
Epidemiology
• 8,296 cases provisionally reported in the United States in 2002, the highest number of reported cases since 1967.
• Approximately 50% of cases are in adolescents (aged 10-19 years) and adults (aged >20 years).
• Case-fatality rate is 0.8% in infants aged <6 months.
• Transmitted person to person via aerosolized droplets from cough or sneeze or by direct contact with secretions from the respiratory tract of infectious persons.
• Incubation period 6-20 days; usually 7-10 days.
• Highly contagious; 80% secondary attack rates among susceptible persons.
• Endemic in the United States; epidemic every 3-5 years.
Clinical findings
• Catarrhal period (week 0-1): illness onset insidious (coryza, mild fever, non-productive cough); infants can have apnea and/or respiratory distress.
• Paroxysmal period (week 1-6): paroxysmal cough, inspiratory "whoop," post-tussive vomiting; pneumonia common among infants; infrequent manifestations include seizures.
• Convalescent period (week 6-12): cough paroxysms and intensity gradually decrease.
Laboratory testing
• Nasopharyngeal aspirate or Dacron ™ swab for Bordetella pertussis on Regan Lowe or Bordet-Gengou culture media plate.
• Detection of B. pertussis DNA by PCR.
• Diagnosis confirmed with isolation of B. pertussis or positive B. pertussis PCR test.
Outbreak setting testing
• Confirm outbreak with >1 culture-confirmed case.
• Test persons when pertussis is highly suspected, symptoms are compatible with pertussis, or person has been exposed to a case and has new cough symptoms.
• Do not test contacts without respiratory symptoms.
Recommended treatment
• Prescribe 14-day course of erythromycin.
-Children: 40-50 mg/kg/day divided QID -Adults: 2 g/day divided QID • Alternatively, use trimethoprim (T)-sulfamethoxazole (S).
-Children: 8 mg/kg/day (T); 40 mg/kg/day (S) divided BID -Adults: 320 mg/day (T); 1600 mg/day (S) divided BID • Exclude from school or work for first 5 days.
• Treat persons aged >1 year within 3 weeks of cough onset.
• Treat infants aged <1 year within 6 weeks of cough onset.
Prevention
• Vaccinate children aged 6 weeks-6 years with diphtheria, tetanus toxoids and acellular pertussis vaccine (DTaP A 14-day course of erythromycin, a macrolide antibiotic with substantial in vitro and in vivo activity against B. pertussis, is the recommended antimicrobial for treatment of patients with pertussis and for prophylaxis of close contacts. Treatment and prophylaxis are most effective when erythromycin is administered to patients within 3 weeks of illness onset and to close contacts within 3 weeks of cough onset in the primary case (9). During an outbreak, repeated exposure to pertussis might warrant repeated courses of erythromycin. If erythromycin is poorly tolerated because of gastrointestinal side effects, trimethoprim-sulfamethoxazole can be prescribed; azithromycin and clarithromycin might be effective alternatives in the eradication of B. pertussis in symptomatic patients (9,10). However, effectiveness of azithromycin or clarithromycin as prophylaxis for asymptomatic close contacts in an outbreak setting is not well documented.
Outbreaks of pertussis in adults are controlled through prompt treatment of patients and antimicrobial prophylaxis for close contacts. Acellular pertussis vaccines are licensed in the United States for infants and children aged 6 weeks-6 years (i.e., before the seventh birthday). These vaccines might have a future role in the prevention of disease and control of outbreaks in older age groups (4, 5, 7) .
Accelerated Measles ControlCambodia, 1999-2002
Cambodia is recovering from approximately 30 years of civil war that resulted in the breakdown of the country's public health infrastructure (1) . In 1999, the Ministry of Health initiated a measles-control program with the goal of reducing the annual incidence of measles to <10,000 cases in 2005 by strengthening measles surveillance, improving routine vaccination coverage, implementing supplementary measles immunization activities (SIAs), and providing vitamin A during outbreak investigations and SIAs. This report summarizes measles-vaccination activities and their impact in reducing reported measles cases from 13,827 in 1999 to 1,234 in 2002 and suggests options for future measles-control efforts in postconflict situations.
Routine and Supplementary Vaccination
Routine measles vaccination began at Cambodian health centers in 1986, with outreach activities added in 1990 and SIAs in 2000. The most basic organizational component of the health-care delivery system is the health center, each serving approximately 10,000 persons. Many villages lack easy access to these facilities, and only 30% of children had access to vaccination services during the early 1990s. Since 1990, outreach teams from health centers have visited villages every 4-8 weeks to deliver vaccination and other preventive health services. These outreach services helped increase coverage for measles vaccination in the country from 34% in 1990 to 75% in 1995, although coverage declined to 63% during 1998-1999, after a resurgence of civil unrest in 1997. In 2000, before the initiation of SIAs, measles vaccination coverage increased to 69% (Cambodian Ministry of Health, unpublished data, 2001).
The Cambodian National Immunization Program (NIP), in collaboration with partner agencies, initiated measles SIAs in December 2000 to vaccinate children who were missed by routine services. The initial plan was to vaccinate all children aged 9 months-5 years, regardless of previous vaccination history, in two phases. After Phase I, the subsequent phase was expanded in 2001 to include children aged 9 months-14 years after a review of measles surveillance data indicated that approximately 50% of measles cases occurred in children aged >5 years. To avoid overextending the public health system of the country and compromising the quality of the campaign, the second phase was then divided into two (phases II and III).
Phase I, conducted during December 2000-May 2001, targeted 191,527 children aged <5 years living in remote border areas who were administered multiple vaccines (measles, oral polio vaccine [OPV], diphtheria-tetanus-pertussis vaccine), vitamin A, and mebendazole for helminth control; an 89% coverage rate with measles vaccine was attained. Phase II, conducted during October 2001-April 2002, targeted 2,489,761 children aged 9 months-14 years living in eight provinces in densely populated central areas. These children were administered measles vaccine, OPV (in selected areas), vitamin A, and mebendazole; a 97% coverage rate with measles vaccine was attained. Phase III, which began in October 2002 and will continue through April 2003, will target approximately 2,300,000 children aged 9 months-14 years living in the remaining seven provinces in central areas with measles vaccine, OPV (in selected areas), vitamin A, and mebendazole.
SIAs are conducted in a "rolling" manner, which cover one province at a time by teams comprising local, district, and provincial Expanded Program on Immunization (EPI) staff, with supervision by staff from the national program. Each district is covered in approximately 2 weeks. SIAs are preceded by social mobilization activities in which local volunteers and community leaders publicize the upcoming activities. Temporary vaccination posts operate in the mornings and are followed by house-to-house vaccination in the afternoons. House-to-house vaccination is particularly necessary in densely populated urban areas, where social mobilization might not be as effective as in villages.
Surveillance and Outbreak Response
Data on measles incidence before 1999 are limited. The World Health Organization (WHO) assisted NIP in conducting 30 outbreak investigations during 1999, recording 1,423 cases, including 14 deaths (case fatality ratio: 1%). In addition, 80 (5.6%) persons showed signs of vitamin A deficiency, and six (0.4%) had encephalitis. In 1999, surveillance was strengthened through the addition of an active search for measles cases during routine outreach visits by EPI staff. Outreach visits detected an estimated 95% of reported measles cases (K. Feldon, M.P.H., WHO Cambodia, personal communication, 2002).
On receiving a report of a measles outbreak from an outreach team, an investigation is conducted approximately 1-4 weeks later by provincial, district, and health center staff. In each village, treatment with vitamin A at the WHOrecommended dosage (2) is provided to all persons with measles to prevent complications and as a prophylaxis to all children aged <12 years. Monetary incentives are provided to EPI staff for reporting an outbreak and to national, provincial, district, and health center staff for conducting the investigation.
Serologic confirmation of outbreaks began in three of the 24 provinces in early 2000 and is now standard in eight provinces. Samples are collected from the first five cases of each outbreak. Testing for measles IgM antibodies is conducted by the National Reference Laboratory in Phnom Penh.
Measles Incidence
The peak of measles transmission in Cambodia occurs during the hot dry season (November-April). In 1999, when the surveillance system covered six of 24 provinces, NIP received reports of 13,827 measles cases. (Table) . Among patients aged <10 years, the proportion with a history of previous measles vaccination has remained steady, ranging from 23% in 2000 to 27% in 2002.
Editorial Note: The marked decrease in the annual number of reported measles cases in Cambodia during 2000-2002 is attributable in part to increases in routine vaccination coverage and to SIAs conducted during the previous 3 years. In addition, the decrease might reflect the natural decline in incidence following an epidemic. Consistent with the low measles vaccination coverage in Cambodia, the majority of cases continue to occur among children aged <10 years and among unvaccinated persons.
Providing routine vaccinations through outreach visits to villages has improved vaccination coverage in a country whose public health infrastructure was destroyed by civil unrest and is being rebuilt. Although vaccination activities began in 1986 with the formation of EPI, insecurity in the countryside restricted the program to the capital and the surrounding provinces. Large areas of the country remained inaccessible until 1996, and only in 1998, when hostilities ceased, was travel possible throughout the country.
Outreach visits also are a major component of the enhanced measles surveillance system that was established in 1999 and helped overcome the lack of information available in healthcare facilities. The majority of Cambodian children with measles are not brought to health-care facilities because of a traditional belief that children should be kept at home during the period of rash; as a result, health-care facility records are not useful for measles surveillance. In addition, health-care workers do not inquire routinely about a history of measles when evaluating a child with possible measles complications (e.g., otitis media, pneumonia, diarrhea, encephalitis, or corneal ulceration or scarring) (S. Sarath, M.D., NIP, Cambodia, personal communication, 2002).
In addition, the strategy of implementing "rolling" SIAs effectively reaches children who missed routine vaccination in infancy. SIAs have been conducted in phases because of the limited health staff trained in administering injections and inadequate cold chain facilities in Cambodia. With this approach, a district is covered thoroughly, ensuring a highquality campaign and a high rate of vaccination coverage.
The findings in this report are subject to at least four limitations. First, because the quality of surveillance and vaccinecoverage data has improved substantially since 1999, comparisons with pre-1999 data are difficult. Second, current surveillance systems might underreport the number of cases in younger children and in persons from remote areas. Third, as measles incidence (and the positive predictive value of clinical diagnosis) decreases, the lack of capacity for laboratory confirmation might lead to overreporting of true measles cases. Finally, estimating vaccination coverage with the administrative method depends on accurate population estimates and might overestimate the true coverage.
For measles control to be achieved, Cambodia will need to 1) increase routine vaccination coverage further by using a combination of fixed vaccination sites and outreach services, 2) continue periodic SIAs to reach children missed by routine services, and 3) further strengthen measles surveillance by enhancing data management and laboratory capacity. As the number of measles cases decreases, laboratory confirmation of all reported outbreaks will be necessary, requiring extension of laboratory confirmation to all provinces. Lessons learned in Cambodia might be useful in planning measlescontrol strategies in other postconflict settings, especially in areas with few trained health staff and limited transportation and cold chain facilities. (Table 1) ; data were not weighted if the overall response rate (i.e., the school response rate multiplied by the student response rate) was <60%. All 81 public high schools in New Hampshire were invited to participate in the survey. Classes in participating schools were sampled at random, and all students in selected classrooms were eligible to participate. NHYTS was conducted in public schools in grades 7-8 during March-May 2000 and in grades 6-12 during October-November 2001 (Table 1) . The survey used a two-stage cluster sample design; schools were selected with probability proportional to size, and classrooms in schools were selected at random. All students in selected classrooms were eligible to participate. The 2001 survey was divided into two separate samples, one for middle schools (grades 6-8) and one for high schools (grades 9-12). Analysis of middle school data was restricted to grades 7-8. In all surveys, local parental consent procedures were followed before survey administration. Among high school students in the 2001 NHYTS, 25.3% (95% confidence interval [CI]=21.7%-28.9%) were current smokers (i.e., reported having smoked cigarettes on >1 of the 30 days preceding the survey), which is significantly lower than the 1995 weighted result from NHYRBS (36.0%; 95% CI=33.2%-38.8%). Declines were significant for females and for students in grades 9 and 11 (Table 2 ). Among middle school students surveyed in NHYTS in 2000 and 2001, current smoking among students in grades 7-8 declined from 12.0% (95% CI=9.4%-14.6%) in 2000 to 6.3% (95% CI=4.2%-8.4%) in 2001; declines were significant for males and for students in grade 7 (Table 3) . At least four explanations might account for the decline in adolescent smoking prevalence in New Hampshire. First, during 1997-2001, the price of cigarettes increased 100%, from $1.77 per pack to $3.53 (5) . Of this increase, $1.39 was from price increases by the tobacco industry, $0.27 was from state excise tax, and $0.10 was from federal excise tax. Previous studies indicate that increases in tobacco prices decrease smoking prevalence, particularly among youth (6) . Second, although the state's tobacco-control program was funded at a low level during 1995-2001, it contained some components of a comprehensive program, including efforts to develop community programs and to begin countermarketing (4). Third, in fiscal year 2001, the neighboring states of Maine, Massachusetts, and Vermont had comprehensive tobacco-control programs funded above the CDC-recommended minimum level (7) . Because media markets for these three states encompass large parts of New Hampshire, those states' countermarketing efforts probably affected New Hampshire. Finally, national efforts at tobacco control, along with media coverage of the tobacco industry at the time of the adoption of MSA, also might have had an impact.
Price increases and control efforts that affect adolescents also are expected to have an impact on tobacco use by adults. (5) . An increase of 10% in cigarette prices is generally estimated to result in a 3%-5% decline in cigarette sales (6) . Although the decline in sales in New Hampshire was smaller than predicted, sales figures might in part reflect sales to residents of neighboring states, where cigarettes are more expensive.
The findings in this report are subject to at least four limitations. First, trend analysis for smoking prevalence among high school students was limited by the lack of weighted data from NHYRBS since 1995. Second, data from the 2000 NHYTS did not include either students in grade 6 or those in high school, which limited the comparison to the 2001 NHYTS to students in grades 7-8. Third, neither survey included adolescents in private schools or those who had dropped out of school. However, this should not affect the analysis of trends because the percentage of students in these categories did not change substantially during the study period (9; K. Schoeneman, New Hampshire Department of Education, personal communication, 2002). Finally, data used to assess changes in smoking prevalence among high school students were obtained from two different surveys. Although both surveys contained identical questions on smoking prevalence and were administered in the same manner, differences might exist between the two surveys.
New Hampshire plans to repeat NHYRBS in 2003 and is attempting to increase the response rate, particularly among schools, to ensure that the data can be weighted. The state also intends to repeat NHYTS in grades 6-12 in 2004. The remaining elements of New Hampshire's comprehensive tobacco-prevention and -control program are being implemented. When fully operational, the program should hasten the decline in smoking among adolescents and begin to decrease prevalence among adults. 
Notice to Readers

Changes in National Notifiable Diseases List and Data Presentation
This issue of MMWR incorporates modifications to Tables I and II Cases of Notifiable Diseases, United States. This year, the modifications add diseases designated nationally notifiable by the Council of State and Territorial Epidemiologists (CSTE) in conjunction with CDC. As of January 1, 2003, three disease have been added to the list of nationally notifiable diseases: chronic hepatitis B infection, hepatitis C virus infection (past or present), and varicella (Table 1) . Incidence data for chronic hepatitis B infection and hepatitis C virus infection (past or present) will not be presented in the weekly MMWR tables pending evaluation of the data by the Division of Viral Hepatitis, National Center for Infectious Diseases. Except where indicated, National Notifiable Diseases Surveillance System (NNDSS) data presented in the notifiable disease tables are transmitted to CDC through the National Electronic Telecommunications System for Surveillance (NETSS). Additional information about nationally notifiable diseases, NNDSS, NETSS, and CSTE is available at http://www.cdc.gov/epo/dphsi/phs.htm and http:// www.cste.org.
Modifications to Table I
Provisional incidence data for diseases with annual incidence of <300 cases in the United States or diseases that are designated as notifiable in <25 states are presented in Table I . Measles (total), mumps, rubella, and congenital rubella syndrome data have been added to Table 1. A Table I footnote will specify the total number of indigenous and imported measles cases comprising total reported measles incidence.
Modifications to Table II
Provisional incidence data for diseases with annual incidence of >300 cases in the United States and diseases that are designated as notifiable in >25 states are presented in Table II 
Notice to Readers
CDC and ATSDR Symposium on Statistical Methods
The Ninth Biennial Symposium on Statistical Methods sponsored by CDC and the Agency for Toxic Substances and Disease Registry (ATSDR) will be held January 28-29, 2003, in Atlanta, Georgia, at the Crown Plaza Ravinia. A short course, "Modeling and Analysis Using Monte Carlo Methods," will be offered January 27, along with the symposium. Presentations will include applications of study designs that have improved public health decision-making, alternate study designs and implications for public health decision-making processes, decision-making algorithms and related software applications and development, and statistics and policymaking in the face of uncertainty. The symposium and course are open to the public, and there is no charge to attend. Registration and additional information about the symposium are available from CDC at http://www.cdc.gov/od/ads/sag. - -333  845  Ark.  --------33  124  La.  --------11  97  Okla.  --------15  99  Tex.  --------274  525   MOUNTAIN  ------5  11  43  170  Mont. - -
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